Feb 26, 2026 04:01PM
Feb 26, 2026 04:01PM
Jan 12, 2026 07:00AM
Jan 12, 2026 07:00AM
Nov 13, 2025 05:10PM
Nov 12, 2025 04:01PM
Nov 6, 2025 07:30AM Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
Oct 9, 2025 07:01AM
Oct 9, 2025 07:00AM
Oct 3, 2025 06:43AM
Aug 14, 2025 08:01AM
Aug 11, 2025 04:10PM
Jul 1, 2025 08:21AM
Jun 30, 2025 04:02PM Neurogene (NGNE) Announces Registrational Trial Design for Embolden Study of NGN-401 Gene Therapy
Jun 30, 2025 04:01PM
Jun 17, 2025 09:17AM
Jun 5, 2025 12:44PM
May 19, 2025 12:29PM
May 16, 2025 03:35AM
May 9, 2025 07:30AM
Apr 28, 2025 05:00PM Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting
Apr 2, 2025 04:01PM
Apr 2, 2025 04:01PM
Mar 24, 2025 04:10PM
Nov 25, 2024 06:47AM
Nov 20, 2024 04:54PM
Nov 19, 2024 04:02PM
Nov 19, 2024 11:07AM BMO Capital Reiterates Outperform Rating on Neurogene (NGNE)
Nov 18, 2024 05:25PM
Nov 18, 2024 06:45AM
Nov 18, 2024 06:45AM
Nov 11, 2024 04:01PM
Nov 11, 2024 04:01PM
Aug 14, 2024 10:14AM
Aug 9, 2024 07:30AM Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates
Aug 7, 2024 07:30AM
Aug 7, 2024 07:30AM
Jul 12, 2024 07:49AM
Jul 1, 2024 07:30AM
Jun 18, 2024 09:26AM
Jun 11, 2024 05:04AM
Jun 3, 2024 07:30AM Neurogene (NGNE) Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program
Jun 3, 2024 07:30AM
May 10, 2024 07:30AM
Mar 21, 2024 07:34AM
Mar 18, 2024 04:14PM
Jan 5, 2024 07:01AM
Jan 5, 2024 07:00AM
Dec 19, 2023 07:00AM Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million
Jul 18, 2023 06:31AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All